Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189152

SCHEMBL7189152

SCHEMBL7189152

Cc1cc(C)c(C(=O)C(P=O)c2ccccc2)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ SLC6A2 P23975 2/20 0.37
▸ SLC6A4 P31645 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ LMNA P02545 5/20 0.36
▸ GAA P10253 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MCOLN3 Q8TDD5 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ATM Q13315 1/20 0.35
▸ ACP3 P15309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175012 0.87 L3MBTL1 (0.46) L3MBTL1LMNAHTTTDP1ATM
SCHEMBL7183330 0.86 CYP1A2 (0.37) L3MBTL1LMNAALDH1A1
SCHEMBL7177680 0.84 L3MBTL1 (0.36) L3MBTL1LMNAGAAHTTALDH1A1
SCHEMBL18823101 0.80 L3MBTL1 (0.52) NPSR1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL14781389 0.80 SRC (0.47) NPSR1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL5999762 0.78 LMNA (0.53) NPSR1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL7189027 0.77 FABP3 (0.43) L3MBTL1LMNAGAAALDH1A1HPGD
SCHEMBL9874802 0.77 LMNA (0.42) NPSR1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL7188486 0.77 SLC6A2 (0.38) NPSR1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL7181408 0.77 NPSR1 (0.36) NPSR1L3MBTL1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NPSR1 2669/4885L3MBTL1 302/4885SLC6A2 3653/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NPSR1 3007/4885L3MBTL1 126/4885SLC6A2 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.